The article discusses the impact of SARS-CoV-2 on the cardiovascular system, highlighting the risk of acute and chronic cardiovascular damage in patients with COVID-19. SARS-CoV-2 enters host cells via the ACE2 receptor, which is present in the heart and lungs, leading to myocardial injury and chronic cardiovascular issues. The virus can cause severe respiratory symptoms, but some patients exhibit cardiovascular symptoms such as heart palpitations and chest tightness, often before respiratory symptoms. The article notes that patients with underlying cardiovascular diseases (CVDs) are at higher risk of severe illness and death from COVID-19. The mechanisms of myocardial injury include ACE2-related pathways, cytokine storms, and respiratory dysfunction. Long-term effects of SARS-CoV-2 on the cardiovascular system are also discussed, with evidence suggesting that even after recovery from SARS-CoV, some patients experience metabolic disorders. Patients with pre-existing CVD are more likely to develop severe symptoms and complications from SARS-CoV-2 infection. The use of antiviral drugs during treatment may pose cardiovascular risks, necessitating careful monitoring. The article concludes that cardiovascular protection is crucial during the treatment of COVID-19, as SARS-CoV-2 can cause significant damage to the heart and cardiovascular system. The study emphasizes the need for further research to understand the mechanisms of SARS-CoV-2-induced cardiovascular damage and to develop effective treatments.The article discusses the impact of SARS-CoV-2 on the cardiovascular system, highlighting the risk of acute and chronic cardiovascular damage in patients with COVID-19. SARS-CoV-2 enters host cells via the ACE2 receptor, which is present in the heart and lungs, leading to myocardial injury and chronic cardiovascular issues. The virus can cause severe respiratory symptoms, but some patients exhibit cardiovascular symptoms such as heart palpitations and chest tightness, often before respiratory symptoms. The article notes that patients with underlying cardiovascular diseases (CVDs) are at higher risk of severe illness and death from COVID-19. The mechanisms of myocardial injury include ACE2-related pathways, cytokine storms, and respiratory dysfunction. Long-term effects of SARS-CoV-2 on the cardiovascular system are also discussed, with evidence suggesting that even after recovery from SARS-CoV, some patients experience metabolic disorders. Patients with pre-existing CVD are more likely to develop severe symptoms and complications from SARS-CoV-2 infection. The use of antiviral drugs during treatment may pose cardiovascular risks, necessitating careful monitoring. The article concludes that cardiovascular protection is crucial during the treatment of COVID-19, as SARS-CoV-2 can cause significant damage to the heart and cardiovascular system. The study emphasizes the need for further research to understand the mechanisms of SARS-CoV-2-induced cardiovascular damage and to develop effective treatments.